Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132958 · ClinicalTrials.gov registry record · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
A Phase 3 study of Endometrial Cancer, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 710
- Enrollment target
- 20
- Study locations
NCT06132958 is a Phase 3 study of Endometrial Cancer that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 710 participants, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06132958, a Phase 3 study of Endometrial Cancer, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 710 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.
Conditions Studied
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Nab-paclitaxel
Study Locations (20)
Florida
- Mount Sinai Cancer Center ( Site 4117) - Miami Beach
- AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 4113) - Orlando
- Florida Cancer Specialists - East ( Site 7000) - West Palm Beach
Georgia
- Northside Hospital ( Site 4112) - Atlanta
- Augusta University ( Site 4116) - Augusta
- Centricity Research Columbus Cancer Center ( Site 4154) - Columbus
Arizona
- HonorHealth (HH) ( Site 8000) - Phoenix
- Arizona Oncology Associates - HOPE ( Site 8002) - Tucson
California
- UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4131) - Los Angeles
- California Pacific Medical Center - Van Ness Campus ( Site 4129) - San Francisco
Louisiana
- University Medical Center New Orleans ( Site 4133) - New Orleans
- TRIALS 365 ( Site 4105) - Shreveport
Alabama
- USA Mitchell Cancer Institute ( Site 4142) - Mobile
Alaska
- Alaska Womens Cancer Care ( Site 4122) - Anchorage
Connecticut
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 4114) - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2023-12-06 |
| Est. Completion | 2028-01-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06132958
The ClinicalTrials.gov registry entry for NCT06132958 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 710 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 4 interventions - of which Sacituzumab tirumotecan is the first listed.
NCT06132958 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Georgia, Arizona.
Frequently Asked Questions
What is clinical trial NCT06132958 about?
NCT06132958 is a clinical study titled "Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)". Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sa...
What is the current status of trial NCT06132958?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 710 participants. The study started on 2023-12-06. Estimated completion is 2028-01-10.
What conditions does trial NCT06132958 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT06132958?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Doxorubicin (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06132958?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06132958 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.